Previous 10 | Next 10 |
Charles River Laboratories ( NYSE: CRL ) gained in the pre-market trading Friday after Jefferies upgraded the non-clinical contract research organization (CRO) to Buy from Hold, noting the company’s prospects in the market for non-human primates (NHP). The analysts ...
Summary Ariel Investments’ 13F portfolio value decreased from $11.27B to $10.02B this quarter. They increased Gentex, Resideo Technologies, and Boyd Gaming while reducing Adtalem Global Education, J. M. Smucker, Aflac, and Trip.com. The top three positions are Baidu, Ph...
Summary Halvorsen's 13F portfolio value decreased from $24.74B to $21.86B this quarter. The number of positions increased from 56 to 82. Viking Global added McKesson, American International Group, and Intuit while decreasing T-Mobile US, General Electric, and Brookfield Asset Mana...
Summary Seeking Alpha user 'Buyandhold 2012' has been investing for 52 years, starting with a $4k portfolio and building it into an $87M fortune. Forced buyouts aside, he has never sold a single share of stock. He's notorious for only giving "hold" or "buy" ratings, refusing to ev...
Summary Charles River Labs, or "CRL", provides critical discovery, clinical and safety services to nearly all biotech and pharma companies and has built a hard-earned reputation for quality. With rapid advancements in the medical field occurring more and more frequently, the servi...
Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it will present at two upcoming investor conferences in New York, including: Baird 2022 Global Healthcare Conference on Tuesday, September 13 th , at 10:15 a.m. EDT; and Morgan Stanley 20 th ...
Company will perform HQ plasmid production in support of Phase I/II clinical trials for AP-4 Hereditary Spastic Paraplegia Charles River Laboratories International, Inc. (NYSE: CRL) and Cure AP-4 , a non-profit foundation dedicated to raising funds and awareness about Ad...
Contract research organization Charles River Laboratories ( NYSE: CRL ) reached a 52-week low on Tuesday of $205.02. Year to date, shares are down 43% . Over the past year, they are down 54% . Earlier in August, Charles River stock fell after cutting its full...
LabCorp announced that it is pursuing a tax-free spinoff of its Drug Development segment. The transaction will separate a slower-growing, highly profitable cash cow from a high growth business, allowing investors to realize significant value. The advantages of the businesses being...
Turnkey research facility expands network in San Diego, San Francisco, Thousand Oaks and Seattle Charles River Laboratories International, Inc. (NYSE: CRL) today announced the addition of five Charles River Accelerator and Development Lab (CRADL™) locations in Califor...
News, Short Squeeze, Breakout and More Instantly...
Charles River Laboratories International Inc. Company Name:
CRL Stock Symbol:
NYSE Market:
Charles River Laboratories International Inc. Website:
Clinical trials for AAV9 gene therapy bolstered with plasmid and viral vector CDMO expertise Charles River Laboratories International, Inc. (NYSE: CRL) announced today a collaboration with the FOXG1 Research Foundation (FRF) highlighting the patient advocacy group’s model t...
Agreement establishes Charles River as the preferred partner for Autobahn Labs, leveraging drug discovery and development capabilities to accelerate the translation of academic discoveries into novel therapeutics Under the agreement, Charles River will make an equity investment in Aut...
Charles River Laboratories International, Inc. (NYSE: CRL) will release second-quarter 2024 financial results on Wednesday, August 7 th , before the market opens. A conference call has been scheduled to discuss this information on Wednesday, August 7 th , at 9:00 a.m. ET. Investors wi...